ClinicalTrials.gg
CompletedNCT04883736Updated May 12, 2021

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

An Early Phase 1 interventional study of Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% in Acne Vulgaris, sponsored by Taro Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-12.

Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Aug 2020, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
973
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited — none open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Sun Pharmaceutical Industries Limited.

Enrollment
12th of 30
973 · median 727
Started
2020
with 1 other
Phase 1
21 of 30
none open now
Registered
20th of 30
by date

Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, this one is the 12th largest by enrollment, is one of 2 that started in 2020, is one of 21 in phase 1, and was the 20th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited is open now. The open studies under Acne Vulgaris, anywhere →

Where they have run

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited as a file.
02

Study summary

To demonstrate the therapeutic equivalence and safety of Tretinoin Gel Microsphere, 0.1% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant) in the treatment of acne vulgaris.

Read the detailed description

A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Tretinoin Gel Microsphere, 0.1% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant) in the treatment of acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris.
  • Subjects who are 18 years of age or older (up to the age of 40) must have provided IRB approved written . Subjects ages 12 to 17 years of age, inclusive, must have provided IRB approved written assent
  • Subjects must have a definite clinical diagnosis of acne vulgaris of severity grade 2, 3, or 4 as per the Investigator's Global Assessment (IGA)

Exclusion criteria

Exclusion Criteria:

  • Female Subjects who are pregnant, nursing or planning to become pregnant during study participation
  • Subjects with a history of or allergy to tretinoin, retinoids, or any of the study medication ingredients.
  • Subjects with the presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications, acne, steroid folliculitis, or bacterial folliculitis).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
973 participants (actual)

Study arms

  • Experimental
    Tretinoin Gel Microsphere, 0.1%

    The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

    Drug: Tretinoin Gel Microsphere, 0.1%

  • Active comparator
    RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%

    The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

    Drug: RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%

  • Placebo comparator
    Placebo Control

    The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

    Drug: Placebo Control

Interventions

  • DrugTretinoin Gel Microsphere, 0.1%

    The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

    Also known as: Test Product

  • DrugTretinoinStudies of TretinoinTretinoin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

    Also known as: Reference Product

  • DrugPlacebo Control

    The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.

    Also known as: Vehicle

06

What researchers measure

Primary outcomes

  1. The percentage change in the inflammatory and non-inflammatory lesion counts

    Demonstration of Therapeutic Equivalence

    Time frame: Baseline to Week 12

07

Study locations

1 site
  • Catawba Research, LLC
    Charlotte, North Carolina 28217, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Apr 2021, 7 months.

Of 44 industry-sponsored phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 7. This study's 7 months is above that.

Counting every sponsor, half of 51 studies reached it within 5 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 12, 2021
StartActual
Aug 31, 2020
Primary completionActual
Apr 16, 2021
CompletionActual
Apr 16, 2021
Last update
May 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04883736
Responsible party
Sponsor
First posted
May 12, 2021
Start date
Aug 31, 2020
Primary completion
Apr 16, 2021
Completion
Apr 16, 2021
Last update
May 12, 2021

Study contacts

Zaidoon A. Al-Zubaidy
study director · Catawba Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion